Faithward Advisors LLC Invests $1.47 Million in Charles River Laboratories International, Inc. $CRL

Faithward Advisors LLC purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 7,379 shares of the medical research company’s stock, valued at approximately $1,472,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CRL. Tema Etfs LLC purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $26,000. Rothschild Investment LLC boosted its holdings in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after acquiring an additional 84 shares during the period. Los Angeles Capital Management LLC purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $42,000. Sfam LLC purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $43,000. Finally, Activest Wealth Management boosted its holdings in Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after acquiring an additional 218 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on CRL shares. Evercore restated an “outperform” rating and issued a $220.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. Mizuho set a $192.00 price target on Charles River Laboratories International in a report on Friday, May 8th. Royal Bank Of Canada started coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target for the company. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, UBS Group upped their price target on Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $208.50.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $188.74 on Tuesday. The stock has a market cap of $9.09 billion, a P/E ratio of -50.20, a price-to-earnings-growth ratio of 2.14 and a beta of 1.46. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The stock has a 50 day moving average of $173.80 and a 200-day moving average of $182.57. Charles River Laboratories International, Inc. has a 52 week low of $143.06 and a 52 week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, beating the consensus estimate of $1.96 by $0.10. The company had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business’s revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.04 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.